Dr. Weber on Discontinuing Immunotherapy in Melanoma

Video

In Partnership With:

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses when to discontinue immunotherapy in patients with melanoma.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses when to discontinue immunotherapy in patients with melanoma.

In early studies involving pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq), patients were treated until progression, Weber says. In melanoma, 15% to 20% of patients are in remission for 3 to 6 years, so treating them until progression is not rational. Questions of duration now arise, but reasoning for discontinuation is not yet established.

Weber says that in reviewing retrospective data, there are some hints of how long patients with melanoma should be treated. In the KEYNOTE-006 trial, patients were randomized to pembrolizumab versus ipilimumab (Yervoy) in the frontline setting. Data show that patients who received a complete or partial response and went off therapy at 2 years did extremely well, Weber says. The remaining rate of remission in those patients was around 90%. The bottom line, he states, is that it is safe to stop immunotherapy at 2 years in some patients with melanoma. This analysis could potentially be extrapolated to lung, bladder, and head and neck cancer.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD